Abstract
No public abstract is available from the verified source records.
Wen‐Yu Hsiao, Kartik Angara, Haider A. Mejbel
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
unpaywall
Confidence 95%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
10.1038/s41575-020-0310-z · 2020
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
10.1111/liv.14093 · 2019
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States
10.1093/jnci/djj234 · 2006
Descriptive epidemiology of cholangiocarcinoma in Italy
10.1016/j.dld.2009.10.009 · 2010
Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia
10.3748/wjg.v18.i5.458 · 2012
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
10.1038/nrgastro.2016.51 · 2016
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors
10.1053/j.gastro.2011.12.005 · 2012
Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features
10.1038/modpathol.2013.241 · 2014
Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma
openalex
Confidence 95%
datacite
Confidence 0%
10.1016/j.hpb.2018.07.021 · 2019
Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities
10.1016/j.humpath.2022.06.001 · 2023
FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH
10.1007/s00428-025-04067-9 · 2025
Genomic spectra of biliary tract cancer
10.1038/ng.3375 · 2015
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
10.1158/2159-8290.cd-17-0368 · 2017
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
10.1158/1078-0432.ccr-18-0078 · 2018
Advances and challenges in targeting FGFR signalling in cancer
10.1038/nrc.2017.8 · 2017
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
10.1158/1078-0432.ccr-14-3212 · 2016
Intrahepatic cholangiocarcinoma with FGFR alterations: A series of Chinese cases with an emphasis on their clinicopathologic and genetic features
10.1016/j.dld.2024.04.025 · 2024
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
10.1158/2159-8290.cd-20-0766 · 2021
Molecular targeted therapies: Ready for "prime time" in biliary tract cancer
10.1016/j.jhep.2020.03.007 · 2020
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
10.1002/hep.26890 · 2014
Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas
10.1038/s41419-021-03548-4 · 2021
Targeted genomic profiling revealed a unique clinical phenotype in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangement
10.1016/j.tranon.2021.101168 · 2021
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice
10.1038/s41416-022-01932-1 · 2022
Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype
2023
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
10.1200/po.17.00080 · 2018
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
10.1038/s41416-022-01908-1 · 2022
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
OncoKB: A Precision Oncology Knowledge Base
2017
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
10.1200/jop.2016.018929 · 2017
Role of the fibroblast growth factor receptor axis in cholangiocarcinoma
10.1111/jgh.12916 · 2015
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
10.3390/ijms21186856 · 2020
Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database
10.1186/s12876-016-0527-z · 2016
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing
10.1634/theoncologist.2013-0352 · 2014
FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma
10.1093/oncolo/oyae170 · 2024
Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
10.1007/s11523-022-00906-w · 2022
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
10.1097/mog.0000000000000171 · 2015
Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion
10.3389/fonc.2025.1527484 · 2025
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
10.1158/2159-8290.cd-21-0697 · 2022
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
10.1016/j.annonc.2022.02.001 · 2022
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
10.1016/j.esmoop.2024.103488 · doi-reference
TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
10.3389/fgene.2022.844800 · doi-reference
CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma
10.1038/s41598-017-17175-7 · doi-reference
Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection
10.1016/j.hpb.2022.05.1341 · doi-reference
Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis
10.1111/liv.15984 · doi-reference
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
10.6004/jnccn.2025.0042 · doi-reference
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
10.1158/2159-8290.cd-16-1000 · doi-reference
FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma
10.1016/j.phrs.2025.107968 · doi-reference
FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?
10.3390/cells11233929 · doi-reference
Receptor tyrosine kinases activate canonical WNT/beta-catenin signaling via MAP kinase/LRP6 pathway and direct beta-catenin phosphorylation
10.1371/journal.pone.0035826 · doi-reference
Activation of FGF receptors by mutations in the transmembrane domain
10.1038/sj.onc.1200983 · doi-reference
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
10.1158/2159-8290.cd-20-1669 · doi-reference
p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice
10.1172/jci62644 · doi-reference
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
10.1038/sj.onc.1210529 · doi-reference
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
10.1038/ncomms7087 · doi-reference
Identification of targetable FGFR gene fusions in diverse cancers
10.1158/2159-8290.cd-13-0050 · doi-reference
Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma
10.1016/j.jhep.2022.11.030 · doi-reference
Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma
10.1097/pas.0000000000000670 · doi-reference
Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions
10.1158/1538-7445.am2021-935 · doi-reference
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy
10.1158/2159-8290.cd-24-0417 · doi-reference